Article

ThromboGenics to develop protein therapies for diabetic eye disease

ThromboGenics NV has started research and development of innovative protein therapeutics to address a biologic target implicated in a range of diabetic eye diseases, such as diabetic macular edema.

Leuven, Belgium-ThromboGenics NV has started research and development of innovative protein therapeutics to address a biologic target implicated in a range of diabetic eye diseases, such as diabetic macular edema (DME).

Through a recent license agreement with Eleven Biotherapeutics, ThromboGenics will develop the company’s proprietary AMP-Rx protein design technology to create a novel therapeutic of ThromboGenics’ selection optimized for improved pharmaceutical characteristics and therapeutic benefits, according to ThromboGenics.

ThromboGenics will have the exclusive license to all future developments and commercialization of the novel protein. In exchange, Eleven Biotherapeutics will receive an undisclosed upfront payment, and is eligible to receive undisclosed development, regulatory, and sales milestone payments, as well as royalties on potential future sales.

Patrik De Haes, MD, chief executive officer (CEO) of ThromboGenics, called the agreement an important step forward in building the company’s ophthalmology franchise, following the recent introduction of Jetrea for the treatment of symptomatic vitreomacular adhesion/vitreomacular traction in the United States and Europe.

“We are confident that by utilizing [Eleven Biotherapeutics’] unique ability to design and optimize protein therapeutics, we will generate an innovative protein therapeutic to address a novel target that we have identified,” Dr. De Haes added. “Our research suggests that protein therapeutics directed at this target could be used to treat a broad range of diabetic eye diseases including DME.”

“Eleven’s novel approach to designing protein therapeutics for ocular diseases, which has been demonstrated with EBI-005, our lead product candidate in phase 1b clinical development for dry eye disease, will be applied to discover and optimize novel modulators of this evolving pathway which is central to ophthalmic disease,” said Abbie Celniker, president and CEO of Eleven Biotherapeutics. “This collaboration validates Eleven’s unique approach to rational protein engineering through novel structures, enhanced biophysical properties, and more effective targeting in disease pathways.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.